Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act

Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.

Ozekibart’s BLA for chondrosarcoma is under FDA review with an April 14, 2027 PDUFA date, supported by strong PFS and disease control data.

INBRX-106 shows promising early efficacy as a PD-1 enhancer in HNSCC, with pivotal PFS data expected in Q4 2026 and Phase 3 initiation in Q3 2026.

INBX’s near-term catalysts include regulatory decisions, pivotal data readouts, and potential expansion into CRC and ES, but it faces regulatory, funding, and execution risks.

I believe the market has been viewing Inhibrx (INBX) too narrowly. While it's true that Inhibrx appears to be a pre-commercial cancer treatment biotech firm with two drug candidates (ozekibart and INBRX-106) targeted at treating a